Demo Sign up Log In

Regeneron Pharmaceuticals (REGN)

EBITDA

$1.66B

Quarterly · Period ending: Jun 30, 2026 · USD

REGN EBITDA

Latest reported$1.66Bperiod endingJun 30, 2026

Latest reported$1.66Bperiod endingJun 30, 2026

REGN Quarterly EBITDA ($1.20M → $1.66B)

Quarterly EBITDA

High-resolution chart · PNG

REGN ebitda history

Quarterly · USD. Dates are reporting period ends; fiscal years can differ from calendar years.

Regeneron Pharmaceuticals EBITDA — Quarterly (USD)
Period ending	EBITDA (USD)
Jun 30, 2001	-16,666,000
Mar 31, 2001	-13,382,000
Dec 31, 2000	-8,214,000
Sep 30, 2000	-14,333,000
Jun 30, 2000	-2,837,000
Mar 31, 2000	-7,554,000
Dec 31, 1999	200,000
Sep 30, 1999	-4,200,000
Jun 30, 1999	-7,500,000
Mar 31, 1999	-9,700,000
Dec 31, 1998	-5,500,000
Sep 30, 1998	-1,700,000
Jun 30, 1998	1,500,000
Mar 31, 1998	-4,000,000
Dec 31, 1997	2,300,000
Sep 30, 1997	-100,000
Jun 30, 1997	-2,500,000
Mar 31, 1997	-2,900,000
Dec 31, 1996	-2,900,000
Sep 30, 1996	-2,900,000
Jun 30, 1996	-2,200,000
Mar 31, 1996	-3,200,000
Dec 31, 1995	-1,400,000
Sep 30, 1995	-800,000
Jun 30, 1995	200,000
Mar 31, 1995	-500,000
Dec 31, 1994	-3,900,000
Sep 30, 1994	-2,600,000
Jun 30, 1994	-9,000,000
Mar 31, 1994	-9,500,000
Dec 31, 1993	-10,300,000
Sep 30, 1993	-8,500,000
Jun 30, 1993	-9,100,000
Mar 31, 1993	-8,500,000
Dec 31, 1992	-5,500,000
Sep 30, 1992	-5,100,000
Jun 30, 1992	-3,000,000
Mar 31, 1992	-2,800,000
Dec 31, 1991	-3,400,000
Sep 30, 1991	-2,300,000
Jun 30, 1991	-1,800,000
Mar 31, 1991	2,000,000
Dec 31, 1990	-7,000,000
Sep 30, 1990	1,300,000
Jun 30, 1990	1,200,000
Mar 31, 1990	1,200,000

Data is provided for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results.